A mixed shelf offering indicates that Soleno Therapeutics may issue new securities, which could dilute the value of existing shares. However, without knowing the size of the offering, it's difficult to assess the full impact. Typically, the market reacts negatively to the potential dilution of shares, hence the negative score. The relevance is 100 as the news is directly about SLNO, and the importance is set at 75 due to the potential financial implications for the company and its shareholders. The confidence level is at 70, reflecting the uncertainty about the size of the offering.